KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. (Q27824867)
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | No label defined |
||
| English | KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. |
scientific article |
Statements
2 references
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer (English)
Astrid Lièvre
Delphine Le Corre
Bruno Landi
Jean-François Emile
Jean-François Côté
Gorana Tomasic
Christophe Penna
Michel Ducreux
Philippe Rougier
Frédérique Penault-Llorca
Identifiers
2 references
2 references